Ipamorelin - 10MG

Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates endogenous growth hormone (GH) release via the GHS receptor, with minimal impact on other pituitary hormones or the HPA axis.^[1][2] In vitro and in vivo, Ipamorelin shows GH-releasing potency comparable to GHRP-6 but a unique selectivity profile: it does not significantly raise ACTH or cortisol even at doses far above those needed for maximal GH release—unlike GHRP-2/6.^[1]

PK/PD modeling in healthy volunteers shows a rapid, dose-dependent, transient GH rise, peaking ~40 minutes post-infusion with a terminal half-life ≈2 hours; GH returns to baseline within hours with no prolonged secretion. The exposure–response fits an indirect model with SC₅₀ ≈ 214 nmol/L.^[2]

Mechanistically, Ipamorelin acts independently of GHRH, involving pituitary and hypothalamic sites (e.g., modulation of somatostatin tone and/or direct somatotroph stimulation).^[1][3][4] Its GH-releasing effect is synergistic with GHRH and is preserved across ages, though attenuated in some hyposecretory states.^[3][4][5] Chronic dosing in animals increases volume density of GH secretory granules in somatotrophs, indicating enhanced storage/release capacity.^[6]

Preclinically, Ipamorelin increases longitudinal bone growth and body weight dose-dependently without altering IGF-I/IGFBPs or bone turnover markers, and without reducing pituitary GH content.^[7] In steroid-induced catabolism models, it improves nitrogen balance and reduces hepatic urea synthesis, supporting potential utility in catabolic states.^[8] Some GHSs—including Ipamorelin—may increase adiposity via GH-independent mechanisms (e.g., higher food intake, leptin secretion).^[9]

Ipamorelin is generally well tolerated at pharmacologically active doses in clinical studies.^[2] Its GH selectivity with minimal ACTH/cortisol effect makes it a candidate for conditions requiring GH stimulation (e.g., GH deficiency, aging, catabolism), pending definition of optimal dosing and long-term safety. Typical animal research doses span microgram–milligram; human studies have used 15-minute infusions from ~4.2 to 140 nmol/kg.^[2]

References

1. Raun K, Hansen BS, Johansen NL, et al. Eur J Endocrinol. 1998;139(5):552-61. doi:10.1530/eje.0.1390552.
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharm Res. 1999;16(9):1412-6. doi:10.1023/a:1018955126402.
3. Camanni F, Ghigo E, Arvat E. Front Neuroendocrinol. 1998;19(1):47-72. doi:10.1006/frne.1997.0158.
4. Ghigo E, Arvat E, Muccioli G, Camanni F. Eur J Endocrinol. 1997;136(5):445-60. doi:10.1530/eje.0.1360445.
5. Ghigo E, Arvat E, Camanni F. Ann Med. 1998;30(2):159-68. doi:10.3109/07853899808999399.
6. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Histol Histopathol. 2002;17(3):707-14.
7. Johansen PB, Nowak J, Skjaerbaek C, et al. Growth Horm IGF Res. 1999;9(2):106-13. doi:10.1054/ghir.1999.9998.
8. Aagaard NK, Grøfte T, Greisen J, et al. Growth Horm IGF Res. 2009;19(5):426-31. doi:10.1016/j.ghir.2009.01.001.
9. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Biochem Biophys Res Commun. 2001;280(1):132-8.
10. Merriam GR, Schwartz RS, Vitiello MV. Endocrine. 2003;22(1):41-8.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles (use aliquots).
• Solvent compatibility: Choose sterile solvent compatible with your protocol; filter-sterilize if required by your procedures.
• Labeling: Clearly label aliquots with concentration, solvent, and date of preparation.

Storage guidance is general for research peptides and may be adjusted per your lab SOP.